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Abstract 
Dendrimers are hyperbranched synthetic well-defined molecules with a number of potential 
applications, especially in relation to the need for new antiviral agents. One subclass of dendrimers 
are peptide derivatized-dendrimers which consist of a peptidyl branching core and covalently 
attached surface peptide functional units. Few studies have addressed the potential uses of peptide  
dendrimers as direct-acting antiviral agents. Here, we report on the ability of two peptide 
dendrimers, SB105 and SB105_A10, to directly and almost completely inhibit human 
cytomegalovirus (HCMV) replication in both primary fibroblasts and endothelial cells; the agents 
were also found to inhibit murine CMV replication, whereas they were not able to inhibit the 
adenovirus or vesicular stomatitis virus. The peptide dendrimers prevented adsorption of the 
HCMV to cells at 4° C, whereas SB104, a dendrimer with a different amino acid sequence within  
the functional group and minimal anticytomegaloviral activity, was ineffective in blocking HCMV 
attachment. In effect, SB105_A10 bound to human cells through an interaction with cell surface 
heparan sulfate and thereby blocked virion attachment to target cells. These results indicate that the 
SB105 and SB105_A10 dendrimers could provide a useful starting point for the development of  
novel molecules to block HCMV infection. 
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1. Introduction 
Human cytomegalovirus (HCMV) is an important and ubiquitous opportunistic viral pathogen 
which generally causes asymptomatic infections in healthy individuals (Landolfo et al., 2003; 
Mocarski et al., 2006; Britt, 2008). However, HCMV infections are a major cause of morbidity and 
mortality among immunocompromised patients, such as recipients of bone marrow and solid-organ 
transplants and AIDS patients (Britt, 2008) for whom prolonged antiviral therapies are often 
necessary. The current therapy for the treatment of HCMV infections relies upon the use of six 
drugs: ganciclovir (GCV), valganciclovir, foscarnet (FOS), cidofovir (CDV), fomivirsen (ISIS  
2922) and maribavir (Michel and Mertens, 2006; De Clercq, 2008). Despite the clinical benefits, the 
current standard therapy for HCMV disease also carries disadvantages, including dose-related 
toxicities and the existence of drug-resistant strains. Thus, a great need exists for the development 
of new anticytomegaloviral agents with reduced toxicity and that can also face the clinical problems  
resulting from the emergence of drug-resistant isolates (Michel and Mertens, 2006). In response to 
this urgent need for new antiviral agents, dendrimer-based molecules have been recognised as 
having a large number of potential therapeutic applications (Rosa Borges and Schengrund, 2005; 
Greco et al., 2007). Dendrimers are highly branched macromolecules synthesized from a variety of 
polyfunctional cores in order to present multiple functional groups on the surface layer. Their 
hyperbranched structures enable a given molecular motif to be exposed in a highly multivalent 
fashion thus offering an efficient means of presenting multiple ligands, or sites of contact, on a 
single molecule (Cloninger, 2002; McCarthy et al., 2005). While the dendrimer core may vary, the 
surface functional groups in the antiviral dendrimers are represented by carbohydrates, anions or 
peptides (Rosa Borges and Schengrund, 2005). The development of peptide-derivatized antiviral 
dendrimers does not appear to have received a comparable amount of attention to that of the 
carbohydrate- or polyanionic-derivatized dendrimers. The aim of this study was to identify and 
characterize the anticytomegaloviral activity of novel peptide derivatized-dendrimers. They were 
derived from the M6 prototype, a tetrabranched dendrimer synthesized on a lysine core which 
tethers four 10-mer peptide chains in lysine and  positions (Pini et al., 2005). M6 has been 
shown to have an antibacterial activity against members of the Enterobacteriaceae and against 
clinical isolates of multidrug-resistant Pseudomonas aeruginosa (Pini et al., 2005). Its mechanism 
of action is thought to rely upon its interference with bacterial lipopolysaccharides (which causes 
the perforation of cell membranes without destroying external cell morphology) and with bacterial 
DNA (Pini et al., 2007). M6 was further shown to be endowed with high resistance against blood 
proteases, low hemolytic activity and low cytotoxic effect upon eukaryotic cells, thus making it a 
promising candidate for the development of new antibacterial and/or antiviral drugs (Pini et al., 
2007). 
 
2. Materials and Methods 
2.1 Cells, culture conditions, and viruses.  
Low-passage human embryonic lung fibroblasts (HELFs) were grown as monolayers in Eagle’s  
minimal essential medium (Gibco-BRL) supplemented with 10% fetal bovine serum (FBS; Gibco- 
BRL), 1 mM sodium pyruvate, 2 mM glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin 
sulfate. The EGFP-expressing reporter cell lines UL54 2F7 and UL112/113 1B4 (Luganini et al.,  
2008b) were cultured in monolayer in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco - 
BRL) supplemented with 10% fetal bovine serum (FBS; Gibco-BRL), 2 mM glutamine, 100 U/ml  
penicillin and 100 g/ml streptomycin sulfate. Human umbilical vein endothelial cells (HUVECs),  
obtained by trypsin treatment of umbilical cord veins, were grown in endothelial growth medium  
(EGM-2; Cambrex Bio Science, Walkersville, MD) supplemented with 2% FBS, human 
recombinant vascular endothelial growth factor, basic fibroblast growth factor, human epidermal  
growth factor, insulin growth factor 1, hydrocortisone, ascorbic acid, heparin, gentamicin, and  
amphotericin B (1 g/ml each). Experiments were performed with cells between passages two and  
six. NIH 3T3 cells were grown as monolayers in Dulbecco’s modified Eagle’s medium (Gibco-
BRL) supplemented with 10% donor bovine serum (Gibco-BRL), 2 mM glutamine, 100 U/ml 
penicillin, and 100 g/ml streptomycin sulfate. The HCMV strain AD169, obtained from the ATCC 
(VR538), was propagated in HELFs infected at a multiplicity of infection (M.O.I.) of 0.01 PFU/cell, 
incubated in minimal essential medium supplemented with 1% heat-inactivated FBS and cultured 
until a marked cytopathic effect could be observed. Virus stocks were then prepared by sonicating 
the cells, followed by centrifugal clarification and titration using a standard plaque assay on HELFs. 
HCMV TB40 UL32-EGFP is a recombinant HCMV TB40 strain in which enhanced green 
fluorescence protein (EGFP) is fused to the C-terminal end of the UL32 gene (Laib Sampaio et al., 
2005 ). It was propagated on HELFs, pelleted through a 20% sorbitol cushion, and titrated as 
described above for HCMV AD169. HCMV VR1814 and HCMV AL1 are derivatives arising from 
clinical isolates recovered from a cervical swab from a pregnant woman (Revello et al., 2001) and 
the bronchoalveolar lavage fluid of a lung transplant recipient respectively. These strains were 
propagated in HUVECs and titrated by the indirect immunoperoxidase staining procedure on 
HELFs using a monoclonal antibody (MAb) reactive to the HCMV IE1 and IE2 proteins (clone 
E13; Argene Biosoft) (Revello et al., 2001). 
HCMV VR5438 and TR are GCV-resistant strains isolated from AIDS patients undergoing GCV  
therapy and that developed CMV retinitis: their effective IC50 are 18 M for VR5438 and 33 M  
for TR. Nucleotide sequence analysis of their UL97 gene revealed amino acid alterations of codon 
595 (Leu-Phe) for VR5438 and the lack of codons 591-594 for TR (Gerna et al., 1998; Baldanti et  
al., 2002; Smith et al., 1998). VR5438 and TR strains were propagated in HELFs and titrated by the 
indirect immunoperoxidase staining procedure on HELFs using a monoclonal antibody (MAb) 
reactive to the HCMV IE1 and IE2 proteins (clone E13; Argene Biosoft) (Revello et al., 2001). The 
murine cytomegalovirus (MCMV) strain Smith (ATCC VR194) was propagated in NIH 3T3 cells 
and titrated by standard plaque assay. The vesicular stomatitis virus (VSV) serotype ‘Indiana’ and a  
clinical isolate of the adenovirus were propagated and titrated by standard plaque assay on HELFs. 
2.2 Dendrimers and antiviral substances.  
Peptide grade reagents, resins and solvents were used for SPPS (solid phase peptide synthesis) and  
were supplied by Novabiochem (Darmstadt, Germany). The HPLC grade solvents used in the  
analytical and semipreparative courses were supplied by Sigma-Aldrich (St. Luis, MO). Dendrimer 
synthesis was carried out manually employing Fmoc/tBu chemistry, using 2-(1Hbenzotriazole- 1 
yl)-1,1,3,3-tetramethyluronium-hexafluorophosphate/N,N diisopropylethylamine activation and 
hydroxybenzothriazole /HBTU/diisopropylethylamine in a ratio of 1/1/2. All acidic peptide-based 
dendrimers were synthesized on a preloaded (Fmoc2-Lys)2-Lys- -Ala Wang resin. FMOC 
protection of amines was removed employing 40% piperidine in NMP. The side chain protecting 
groups were: 2,4,6-trimethoxybenzyl (Tmob) for Gln, trityl for Gln and Asn, 2,2,4,6,7- 
pentamethyldihydro-benzofuran-5-sulfonyl (Pbf) for Arg; tert-butyl ether for Ser; 
tertbutyloxycarbonyl (Boc) for Lys and Trp. In particular, the Tmob protective group was preferred 
when Gln was directly linked to the lysine core, while trityl protection was used when Gln was 
present in the N-terminal. All acidic peptides were cleaved from the resins and deprotected by 
treatment with trifluoroacetic acid, water and triisopropylsilane (in the ratio of 95:2.5:2.5).  Reverse 
phase HPLC analyses were performed in gradient mode using 0.1 % v/v TFA in water as solvent A, 
and 0.1 % v/v TFA in acetonitrile as solvent B. Solutions were run at 1 ml/min and detected at 210 
nm. Separation was achieved on a Jupiter Proteo analytical C12 column (4.6 × 250 mm) supplied 
by Phenomenex (Torrance, CA) using a gradient of 5-95 % solvent B over 16 minutes. Peptide were 
purified on a Jupiter Proteo semipreparative C12 column (10 × 250 mm) using a gradient of 20 
60 % solvent B over 15 minutes. The identity and the purity of the final products were confirmed by 
MALDI-TOF mass spectrometry using sinapinic acid as the acidic matrix. MALDI-TOF mass 
spectra were acquired in the positive ion mode. Mass calibration was performed with standard 
peptides covering the range 500-6000 m/z. All purified peptides (HPLCUV purity >95%) were 
lyophilized and then used in all assays as trifluoroacetate salts. The molecular weights of SB104, 
SB105 and SB105_A10 dendrimers are 4506, 5194 and 4682,9 respectively. Fomivirsen (also 
known as ISIS 2922) is a 21-base phosphorothioate oligodeoxynucleotide (5’- 
GCGTTTGCTCTTCTTCTTGCG-3’) complementary to the IE2 mRNA (Azad et al., 1993) was  
synthesized by Metabion International, Germany. All compounds were dissolved in phosphate  
buffer saline (PBS). 
2.3 Antiviral assays.  
For the reduction of viral yield assay, both untreated cells and those incubated with different 
concentrations of peptides for 1 h before infection were infected with HCMV, MCMV, adenovirus,  
VSV or GCV-resistant HCMV clinical isolates (VR5438 and TR) at an M.O.I. of 1 PFU/cell.  
Following virus adsorption (2 h at 37°C), cultures were maintained in medium containing the 
corresponding peptides and then incubated until control cultures displayed extensive cytopathology.  
The cells and supernatants from the antiviral assay were then harvested and disrupted by sonication. 
The extent of virus replication was subsequently assessed by titrating the infectivity of the  
supernatants of cell suspensions on either HELFs (for HCMV, adenovirus and VSV) or NIH 3T3  
cells (for MCMV) as previously described (Luganini et al., 2008a). Plaques were microscopically 
counted and the mean plaque counts for each drug concentration were expressed as a percentage of  
the mean plaque count of the control virus. The number of plaques was plotted as a function of drug  
concentration; the concentrations producing 50 and 90% reductions in plaque formation (IC50 and 
IC90) were determined. Each experimental infection was carried out in duplicate and cell  
suspensions were titrated in duplicate. 
To determine cell viability, HELFs were exposed to increasing concentrations of peptides. After 6 
days of incubation, the number of viable cells was determined using the 3-(4,5-dimethylthiazol-2- 
yl)-2,5-diphenyltetrazolium bromide (MTT) method, as previously described (Pauwels et al., 1988).  
For quantitative EGFP expression analysis, UL54 2F7 and UL112 ⁄113 1B4 cells were seeded in 
24-well plates at a density of 7 x 104 cells. After 24 h, cells were treated with either 10 g/ml of 
one of the various dendrimers (Fig. 2) or with ISIS 2922 (5 ; 1 h later, cells were infected with 
HCMV AD169 (M.O.I. of 5 PFU/cell). At 72 h post-infection (p.i)., the cells were washed with 
PBS and lysed with NP buffer (50 mM Tris-HCl, pH 7-8, 150 mM NaCl, 5 mM EDTA, 15 mM 
MgCl2, 0.15% NP-40) at 4 °C for 30 min. Cell lysates were then centrifuged and the supernatants  
analysed for EGFP content using a Victor3 1420 Multilabel Counter, Perkin Elmer fluorescent  
microplate reader, with excitation and emission filters set at 485 and 535 nm respectively. Each  
experimental infection was carried out in duplicate and lysates were processed in duplicate. 
2.4 Immunoblotting. 
Whole-cell protein extracts were prepared as previously described (Caposio et al., 2007a). Proteins  
were separated by 8% SDS-PAGE and transferred to Immobilon-P membranes (Millipore). Filters 
were blocked overnight in 5% non-fat dry milk in 10 mM Tris-HCl, pH 7.5, 100 mM NaCl and 
0.1% Tween 20 and immunostained with the mouse anti-HCMV IE1 and IE2 MAb (clone E13; 
Argene Biosoft) (diluted 1:200), mouse anti-HCMV UL44 MAb (clone 1202; Goodwin Institute,  
Plantation, FL) (diluted 1:1000), mouse anti-HCMV UL99 MAb (clone 1207; Goodwin Institute)  
(diluted 1:1000) or mouse anti-actin MAb (Chemicon International) (diluted 1:2000). 
Immunocomplexes were detected using sheep anti-mouse immunoglobulin Ab conjugated to 
horseradish peroxidase (Amersham) and visualized by enhanced chemiluminescence (Super Signal; 
Pierce). 
2.5 Quantitative viral nucleic acid analysis. 
Real-time quantitative reverse transcription-PCR (RT-PCR) was performed on an Mx 3000 P 
apparatus (Stratagene) using SYBR Green as a non-specific PCR product fluorescence label as 
previously described (Caposio et al., 2007b; Luganini et al., 2008a). After HCMV infection and cell  
treatment, total cellular RNA was isolated using the Eurozol reagent (Euroclone Ltd., United 
Kingdom) and RNA samples (1 g) were then retrotranscribed at 42°C for 60 min in PCR buffer 
(1.5 mM MgCl2) containing 5 M random primers, 0.5 mM deoxynucleoside triphosphates, and 
100 U Moloney murine leukemia virus reverse transcriptase (Ambion) in a final volume of 20 l. 
Reverse-transcribed cDNAs (2 l), or water as the control, were then amplified in duplicate using 
the Brilliant SYBR Green QPCR master mix (Stratagene) in a final volume of 25 l. Primer 
sequences were as follows: IE1 (sense, 5’-CAA GTG ACC GAG GAT TGC AA-3’; antisense, 5’- 
CAC CAT GTC CAC TCG AAC CTT-3’); IE2 (sense, 5’-TGA CCG AGG ATT GCA ACG A-3’; 
antisense, 5’-CGG CAT GAT TGA CAG CCT G-3’). Following an initial denaturing step at 95°C 
for 2 min to activate 0.75 U Platinum Taq DNA polymerase (Invitrogen), the cDNAs were 
amplified for 30 cycles (95°C for 1 min, 58°C for 1 min, and 72°C for 1 min). For quantitative  
analysis, semi-logarithmic plots were constructed of delta fluorescence versus cycle number and a  
threshold was set for the changes in fluorescence at a point in the linear PCR amplification phase 
(Ct). The Ct values for each gene were normalized to those for -actin with the Ct equation. The 
level of target RNA, normalized to the endogenous reference and relative to that of the mock 
infected and untreated cells, was calculated using the comparative Ct method with the 2- Ct 
equation. 
2.6 Attachment assays. 
The effect of dendrimeric peptides on viral attachment was evaluated by adsorption assay, as  
described by Shogan et al. (2006). To achieve this, prechilled HELF cell monolayers were treated 
with various concentrations of peptides or heparin for 1 h at 4 °C and infected with precooled 200  
PFU of HCMV AD169 in the presence of the compounds for 3 h at 4°. Cells were then washed with  
cold MEM three times to remove unattached virus and compounds, overlaid with a 1.2% 
methylcellulose solution and incubated for 6 days at 37° C. Plates were then fixed and coloured  
with crystal violet for the microscopic counting of plaques. One lane per plate was used as a control 
to confirm that incubation at 4° C only allowed viral attachment and not viral entry. In order to  
establish this, the cells to which the virus had been attached at 4°C were treated with cold acidic 
glycine (0.1 M glycine, 0.150 M NaCl, pH 3.0) for 2 min before being covered with 1.2% 
methylcellulose medium. The number of plaques produced by these control wells was set to 100%. 
For microscopy analysis of HCMV TB40 UL32-EGFP binding to HELFs, cells were grown to 
semi-confluency on glass coverslips in 24-well plates. Then, prechilled cell monolayers were 
treated with 5 g/ml of SB105-A10 or heparin (10 g/ml), and infected with pre-cooled HCMV 
TB40 UL32-EGFP at an M.O.I. of 20 for 2 h at 4°C. Cells infected with EGFP-expressing virus 
were then gently washed twice with ice-cold PBS, fixed in 4% formaldehyde for 10 min on ice and 
examined by fluorescence microscopy following counterstaining with Evans blue (Sigma). Images 
were recorded with an Olympus Fluoview-IX70 inverted confocal laser scanning microscope. 
2.7 Virucidal assay. 
To investigate the effect of dendrimeric peptides on viral infectivity (Shogan et al., 2006),  
dendrimers (5 g/ml) were added to aliquots of HCMV AD169 (104 PFU) and the virus-peptide 
samples were incubated at either 4 or 37°C for various lengths of time. After incubation, the  
samples were diluted with culture medium to reduce the amount of peptide to a concentration that 
was identified as being non-active in the antiviral assay and the residual HCMV infectivity was then 
titrated on HELFs. Plaques were microscopically counted and the mean plaque counts for each 
peptide concentration expressed as PFU/ml on a log10 scale. 
2.8 Heparitinase assay. HELF cell monolayers were pretreated with various concentrations of 
heparinase I or heparitinase I (Sigma) in PBS containing 1 mM CaCl2, 1.5 mM MgCl2, 0.1% 
glucose, and 0.1% bovine serum albumin or with buffer alone for 1 h at 37°C (Silvestri and 
Sundqvist, 2001). Cells were then washed three times with medium prior the analysis of HCMV 
infectivity or the binding of fluorescein isothiocyanate (FITC)-conjugated-SB105_A10 dendrimer. 
Detection of bound fluorescent SB105-A10-FITC was performed on fixed cells (4% formaldehyde 
for 10 min on ice) by fluorescence microscopy following counterstaining with Evans blue (Sigma).  
Images were recorded with an Olympus Fluoview-IX70 inverted confocal laser scanning 
microscope. 
2.9 Data analysis. 
All data were generated from duplicate wells in at least three independent experiments. The effects 
of the dendrimeric peptides at different concentrations were expressed as PFU/ml on a log10 scale 
and the mean plaque count for each drug concentration was expressed as a percentage of the mean 
plaque count of the control virus. Concentrations producing 50 and 90% reductions in plaque 
formation (IC50 and IC90) were calculated by linear regression using the computer 
programGraphPad Prism version 4.0. 
 
 
3. Results 
3.1 SB105 and SB105_A10 inhibit HCMV replication in cell culture. The effects of a 
minilibrary of dendrimeric peptides derived from the M6 prototype (Pini et al., 2005) (Fig. 1) upon 
the in vitro replication of HCMV AD169 laboratory strain were assessed using a cell-based assay 
that relies upon the UL54 2F7-EGFP and UL112/113 1B4-EGFP reporter cell lines (Luganini et al., 
2008b). These cells were generated from the permissive U373-MG cell line in order to express 
EGFP under the control of the HCMV UL54 and UL112/113 early promoters and have been 
validated as being a reliable tool for assessing virus-inhibitory effects in both concentration- and 
time-dependent fashions (Luganini et al., 2008b). As shown in Fig. 2, several peptide derivatized 
dendrimers showed moderate inhibitory activity towards HCMV AD169 replication. However, two 
of them, SB105 and SB105_A10 decreased EGFP expression by over 90 % and were thus chosen 
for further analysis. Furthermore, an unbranched peptide with the same sequence as SB105 (SB 105 
LIN, Fig. 2) showed a minimal inhibitory activity, thus suggesting that the dendrimer structure is  
required to confer an anticytomegaloviral activity to the specific amino acid sequence of the SB105 
surface groups. Pretreatment of HELF cells with SB105 and SB105_A10 peptides, 1 h before 
infection, produced a significant concentration-dependent inhibition of HCMV AD169 replication 
at 6 days p.i. (Fig. 3A). The IC50 and IC90 concentrations for HCMV replication were 0.22 
and 0.77 for SB105 and 0.29 and 1.04 for SB105_A10 respectively. The inhibitory 
effects of SB105 and SB105_A10 were neither virus strain specific nor cell type specific since they 
were also observed in HELFs infected with the clinical isolate AL-1 (IC50 0.23 for SB105 and 
0.25 M for SB105_A10) and in HUVECs infected with the endoteliotropic VR1814 strain (Fig. 
3B) (IC50 0.24 and 0.34 respectively). Moreover, SB105 and SB105_A10 did not 
significantly affect the viability of HELFs or HUVECs in the relevant range of concentrations as 
>90% of cells were still viable after 6 days of treatment with dendrimers at concentrations as high 
as 20 M (Fig. 3A and 3B); this demonstrates that the antiviral activity was not due to cytotoxicity 
of the target cells themselves. We then investigated whether the SB105 and SB105_A10 dendrimers 
interfere with the replication of other viruses. As shown in Fig. 3C, the results obtained with 
MCMV were similar to those observed with HCMV. When preincubated with NIH3T3 cells, the 
dendrimers showed a significant inhibition of MCMV replication and the calculated IC50’s were 
0.67 M and 0,98 M respectively. In contrast, the replication of a clinical isolate of adenovirus as 
well as of a VSV laboratory strain in HELF cells pre-treated with SB105 or SB105_A10 was not 
significantly affected (Fig. 3C). 
Altogether, these results demonstrate that SB105 and SB105_A10 inhibit the in vitro replication of 
HCMV and MCMV, but not that of VSV or adenovirus, and that this antiviral activity is 
independent of cell type and virus strain. 
3.2 SB105 and SB105_A10 inhibit the replication of GCV-resistant strains of HCMV.  
In view of the occurrence of GCV-resistant strains during prolonged treatment therapies, the 
anticytomegaloviral activity of dendrimers in this context was evaluated by measuring the effect of  
SB105 and SB105_A10 upon two GCV-resistant strains, TR and VR5438, that lack drug 
phosphorylation activity due to mutations in the UL97 gene (Smith et al., 1998; Gerna et al., 1998; 
Baldanti et al., 2002). Fig. 3D shows the effects of various concentrations of dendrimers upon viral  
titers determined by measuring the viral yield of virus-infected HELFs at 6 days p.i.. Replication in 
both GCV-resistant strains was significantly impaired by both SB105 and SB105_A10, and their  
respective IC50 values were 0.85 M and 0.49 g/ml for treatment of the TR strain, and 0.78 M 
and 1.2 M of the VR5438 strain. 
3.3 SB105 inhibits the first phases of the HCMV replicative cycle. 
To obtain more insight into the mechanism of peptide derivatized-dendrimers antiviral activity, we 
investigated the effects of SB105 upon overall HCMV gene expression. In order to do this, total cell  
extracts were prepared from HCMV AD169-infected HELFs treated with SB105 for various lengths 
of time post-infection. The extracts were then analyzed for their contents of immediate-early (IEA), 
early (UL44) and late (UL99) proteins by immunoblotting with specific antibodies. Expression  
levels of IEA, UL44 and UL99 were assessed as a reflection of the levels of immediate early, early  
and late protein synthesis. SB105 inhibited the expression of all the assessed HCMV proteins at  
each of the time points analyzed (Fig. 4A). Then, RT-PCR was used to measure IE1 and IE2 mRNA 
levels in HCMV AD169-infected HELFs treated with SB105. As shown in Fig. 4B, and consistent 
with results above, the synthesis of both IE mRNAs was completely prevented by SB105  
throughout the entire viral replicative cycle. This result supports the assertion that SB105 acts at a  
very early stage in the HCMV replicative cycle, that is, before the expression of IE genes. 
Furthermore, incubation with SB105 or SB105_A10 at 1 M after 2 h of virus adsorption did not 
significantly affect HCMV replication in HELFs, in contrast to the strong antiviral effect observed 
when the same dendrimers were added up to 3 h prior to infection (data not shown). This confirms 
that their antiviral activity targets the very early phases of the HCMV cycle, such as adsorption 
and/or entry. 
3.4 SB105 and SB105_A10 dendrimers impair HCMV attachment to target cells. 
To investigate whether the inhibitory activities of SB105 and SB105_A10 are due to the inhibition 
of HCMV adsorption onto cells, prechilled HELFs monolayers were infected with HCMV AD169 
in the presence of SB105, SB105_A10, SB104 (a negative control of HCMV replication inhibition; 
Fig. 2) at various concentrations or heparin (a positive control for inhibition of viral attachment).  
After 3 h at 4°C, cells were washed to remove unattached virus and covered with a solution of 1.2% 
methylcellulose in order to measure the infectivity of HCMV that had successfully attached onto 
cells. As shown in Fig. 5, both SB105 and SB105_A10 clearly impaired the attachment of HCMV 
in a concentration-dependent manner and to a similar degree as observed in the plaque reduction 
assay (Fig. 3A). In contrast, SB104 showed minimal inhibitory activity towards HCMV entry, 
consistent with the lack of any significant antiviral activity as seen in the plaque reduction assay  
(Fig. 2). As expected, heparin blocked the ability of HCMV to bind to HELF cells by inhibiting the 
interaction between the virus and cell surface HPSG (Compton et al., 1993; Isacsoon et al., 2008).  
To investigate further the mechanism of action of SB105 and SB105_A10, we explored the  
possibility that they are able to interact with HCMV particles and thus inhibit viral infectivity. 
HCMV AD169 were incubated with 1 M of SB105, SB105_A10 or SB104 at 4 or 37°C for 
various lengths of time. Following incubation, the virus/peptide mixtures were diluted with medium 
in order to reduce the concentration of dendrimers well below that able to inhibit HCMV 
replication; the residual HCMV infectivity was then titrated on HELFs (Shogan et al., 2006). As  
shown in Fig. 6, the pre-incubation of virions with dendrimers did not significantly affect HCMV 
AD169 at either 4 or 37°C and indicates that their inhibitory activities are not due to the irreversible  
inactivation of virions in solution. Thus, this result suggests that SB105 and SB105_A10 are only  
able to inhibit HCMV infection when they present at the time when the virus attaches to the target 
cell. 
3.5. SB105_A10 dendrimer binds to cellular heparan sulfate.  
To further characterize the mechanism of action of dendrimers, we directly examined their binding 
to cell surface. As shown in Fig. 7A, a fine punctate cell surface pattern of green fluorescence was 
observed in HELFs incubated with a fluorescein isothiocyanate (FITC)-conjugated-SB105_A10 
(SB105_A10-FITC) for 2 h at 4°C, thus indicating the successful binding to cells. To verify that the 
staining was specifically dependent on the dendrimer structure, binding of SB105_A10–FITC was 
competed by the same dendrimer without FITC label, that clearly inhibited the interaction with cell 
surface (Fig. 7A). Moreover, the staining of HELFs from SB105_A10-FITC was prevented by 
soluble heparin as well as by pretreatment with heparinase I or heparitinase I. Thus, these results 
indicate the ability of the dendrimer to bind cellular heparan sulfate (HS) (Fig. 7A). Furthermore, 
the attachment of HCMV UL32-EGFP, a recombinant reporter virus that expresses the EGFP 
protein fused to the capsid-associated tegument protein UL32 and thus generates green fluorescent 
virion particles (Laib Sampaio et al., 2005), was prevented in HELFs pretreated with both enzymes 
(Fig. 7B). Thus, the cleavage of cell surface HS by heparinase or heparitinase treatment was 
effective to block the initial interaction of HCMV with HSPGs (Compton et al., 1993; Isaacson et 
al., 2008). Finally, as expected, SB105_A10 treatment blocked the binding of HCMV UL32-EGFP 
virions to HELFs, further supporting the conclusion that dendrimers prevent HCMV attachment 
(Fig. 7B). Cumulatively, these findings indicate that the mode of action of SB105_A10 towards 
HCMV infection involves the inhibition of virion binding to HPSGs on the surface of target cells. 
 
 
4. Discussion 
Dendrimers are attractive in the terms of their potential use as therapeutic antivirals due to their  
small size (nanomolar), their ease of preparation and functionalization, and their ability to display 
multiple copies of surface groups (multivalency) required for biological recognition processes  
including the initial interactions which occur between an infecting virus and the target cell (Rosa  
Borges and Schengrund, 2005; Heegaard and Boas, 2006). To the best of our knowledge, this is the 
first study to demonstrate an anticytomegaloviral activity of peptide derivatized-dendrimers. The 
SB105 and its derivative SB105_A10 showed a significant dose-dependent inhibitory effect upon 
infection of several HCMV strains (including GCV-resistant clinical isolates) by means of a 
mechanism in which the suppression of the initial attachment of virions to HPSGs on the cell 
surface seems to play a key role in their antiviral activities. Moreover, it appears that their antiviral 
activities are specific for Herpesviruses, since replication of both HCMV and MCMV as well as 
that of HSV-1 and HSV-2 (Luganini et al., unpublished results) was inhibited while negligible 
inhibition was observed for adenovirus and VSV. The antiviral activities of SB105 and SB105_A10 
are likely to stem from the specific amino acid sequence of the peptide surface groups attached to 
the dendrimer scaffold since variation of this sequence was found to reduce or abolish their 
inhibitory actions (Fig. 2). In fact, the screening of twelve distinct dendrimer compounds (Fig. 1) 
with differences in the amino acid sequences of their surface groups lead to the selection of SB105 
and its derivative SB105_A10 in which the Cterminal glutamine residue of the functional 
ASLRVRIKKQ group was removed. Herpesviruses are known to bind polyanionic molecules such 
as heparan sulfate polysaccharides which are usually linked to proteins to form the cell surface 
HSPGs. The initial and essential interaction of virions with HSPGs is a relatively conserved feature 
of herpesvirus entry (Isacsoon et al., 2008). Thus, numerous negatively-charged polyanions have 
been selected to bind herpesvirus envelope components and thereby block virion attachment and 
entry into target cells (Greco et al., 2007). Among these, dendrimers and dendrimer-like molecules 
have recently been generated with surfaces formed of negative charges and screened for potential 
anti-herpes activities. Indeed, in vitro analysis has revealed that sulfonated and carboxylated 
polylysine dendrimers effectively block the HSV-1 and -2 infection of cells and non-primate animal 
studies have shown that they were able to protect animals against an intravaginal HSV-2 challenge 
(Bourne et al., 2000; Bernstein et al., 2003; Gong et al., 2005). However, in addition to inhibiting 
the HSV attachment, the sulfonate ddendrimers were also shown to act at a post-entry level by 
apparently inhibiting HSV DNA synthesis, which suggests that they could be used not only for 
prevention of HSV infection but also as inhibitors of viral replication (Gong et al., 2005). 
Sulfonated polylysine dendrimers, similar to those selected against HSV, were also found to inhibit 
HIV-1 infection and block vaginal SHIV (chimeric simian-human immunodeficiency-1 virus) 
transmission in pigtailed macaques (McCarthy et al., 2005; Rupp et al., 2007). On the basis of these 
results, SPL7013, a lysine-based dendrimer with naphthalene disulfonic acid surface groups, is 
currently being developed as a candidate topical microbicide, known as ViVagel, for the prevention 
of both HIV-1 and HSV-2 transmission (Rupp et al., 2007). However, the characteristics of the 
ASLRVRIKKQ peptide (which functionalizes the SB105 and SB105_A10 dendrimers selected for 
their anticytomegaloviral activity) endow the molecule’s surface with positive charges. It is 
therefore unlikely that they are able form complexes with HCMV envelope glycoproteins and 
therefore inhibit virion attachment in this mode. Consistent with this hypothesis, we observed that 
SB105_A10 binds to human cells in a heparan sulfate-dependent manner since this interaction was 
prevented either by the homologous polysaccharide heparin or by heparinase/heparitinase treatment 
of target cells (Fig. 7). The interaction of SB105 and SB105_A10 with HS polyanion thus lead to a 
block of infection as HS are the initial cellular attachment mojety for HCMV (Compton et al., 1993; 
Isaacson et al., 2008). HCMV is the principal pathogen in transplant recipients; it has also been 
implicated in vascular disorders, such as transplant vasculopathy, restenosis and atherosclerosis that 
are characterized by endothelial cell activation, inflammatory cell infiltration and smooth muscle 
cell proliferation; moreover, HCMV is recognized as the leading viral cause of birth defects (Britt, 
2008). The standard therapy for HCMV disease is associated with considerable adverse side effects, 
and prolonged treatment may lead to the emergence of drug-resistant strains. In addition, the 
antivirals currently used are not able to prevent the reactivation of latent HCMV infection or the 
expression of IE proteins which play crucial roles in viral pathogenesis and immunomodulation. 
The importance of IE functions and the inability of the antiviral therapies currently available to 
prevent their expression has led to the suggestion that the prevention of their expression and/or 
functions may provide an alternative strategy for the inhibition of HCMV reactivation, replication 
and immunopathogenesis (Michel and Mertens, 2006). The identification of novel anti-
cytomegaloviral agents able to block either HCMV entry and/or gene expression at very early 
stages without causing major adverse effects is therefore needed. The potential use of compounds 
targeting virus attachment and entry could be hampered by the cell to- cell spread that characterizes 
recent clinical HCMV isolates (Mocarski et al., 2006). However, in the normal host the release of 
cell-free virus depends on the site of infection, and although cell-free virus transmission during 
hematogenous dissemination is thought to be unlikely because HCMV replication is highly cell-
associated, cell-free virus is commonly found in body fluids such as urine, saliva and breast milk 
and often at high titers (Britt, 2008). Thus, molecules such as SB105 and SB105_A10 that act by 
blocking virus attachment may represent an attractive target for antiviral drug development to 
prevent HCMV transmission via these excretions and to reduce disseminated infections in severely 
immunocompromised patients in which large amounts of cell-free infectious virus have been 
documented in the peripheral blood (Britt, 2008). Our results indicate that SB105 and SB105_A10 
may be attractive candidates for such a new class of antiviral drugs: drugs that exert their effects via 
a novel pathway targeting virus attachment and might have advantages in terms of lacking an 
induction of drug resistance.Their potent anticytomegaloviral activity in vitro warrants the 
execution of further studies to evaluate whether dendrimer treatment can also result in antiviral 
activity in vivo, through the use of animal models of acute infection. Since in vitro experiments 
have demonstrated that SB105 and SB105_A10 inhibit MCMV replication (Fig. 3C), in vivo 
studies would be useful for validating their potential use in the prevention and/or control of HCMV 
infection. 
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Figure 1. Structures of the peptide derivatized-dendrimers. The generic structure of peptide is 
shown. These molecules were synthesized by the addition of four 10-mer peptide chains to a 
tetrameric lysine central core. The amino acid sequence of each dendrimer peptide functional group  
is also shown. 
  
 
 
 
Figure 2. SB105 and SB105_A10 dendrimers inhibit EGFP expression driven by HCMV early 
promoters in UL54 2F7 and UL112/113 1B4 reporter cell lines. UL54 2F7 and UL112/113 1B4 
cells were either mock-infected or infected with HCMV AD169 (M.O.I. of 5 PFU/cell) and, where 
indicated, the cells were pretreated and treated with 2 M of dendrimeric peptides, the SB105-LIN 
or with ISIS 2922 (5 1 h prior to and during the infection period. At 72 h p.i., cell lysates were 
prepared and assayed for quantitative EGFP expression by automated fluorometry. The SB105-LIN 
is an unbranched synthetic peptide with the same sequence as the SB105 peptide surface group. The 
21-bp antisense phosphorothioate oligonucleotide, complementary to the HCMV IE2 mRNA,  
fomivirsen (ISIS 2922), was used as the positive control of the inhibition of EGFP expression. The 
data shown in each column represents the mean ± standard deviation (SD, error bars) of three  
independent experiments performed in duplicate. 
 
 
 
  
 
 
 
 
 
 
Figure 3. Antiviral activity of SB105 and SB105_A10 on productive HCMV replication. A) 
SB105 and SB105_A10 inhibit HCMV AD169 replication. HELFs were infected with HCMV 
AD169 (M.O.I. of 1 PFU/cell) and, where indicated, the cells were treated with increasing 
concentrations of dendrimers 1 h before virus adsorption and throughout the experiment until an 
extensive viral cytopathic effect was observed in the untreated controls. The extent of AD169  
replication was then assessed by titrating the infectivity of supernatants of HELF suspensions using  
a standard plaque assay. Plaques were microscopically counted and the mean plaque counts for each 
drug concentration expressed as a percentage of the control mean count. The number of plaques is  
plotted as a function of drug concentration and the concentrations producing 50 and 90% reductions  
in plaque formation (IC50 and IC90) are shown. Data shown represent means ± SD (error bars) of 
three independent experiments. To determine cell viability, HELF cells were exposed to increasing 
concentrations of peptides. After 6 days of incubation, the number of viable cells was determined 
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method (Pauwels et 
al., 1988). 
B) The replication of the clinical HCMV isolate VR1814 is blocked by SB105 and SB105_A10  
in endothelial cells. HUVEC cells were infected with VR1814 (M.O.I. of 1 PFU/cell) and, where 
indicated, the cells were pretreated and treated with increasing concentrations of dendrimers 1 h  
prior to and during infection until an extensive viral cytopathic effect was observed in the untreated 
control. The extent of VR1814 replication was then assessed by titrating the infectivity of 
supernatants of cell suspensions on HELF cells by the IE antigen indirect immunoperoxidase  
staining technique. Plaques were microscopically counted, and the mean plaque counts for each 
drug concentration were expressed as a percent of the mean count of the control. The number of 
plaques was plotted as a function of drug concentration, and the concentrations producing 50 and  
90% reduction in plaque formation (IC50 and IC90 ) were determined. Data shown represent means 
± SD (error bars) of three independent experiments. HUVEC cells viability was determined as 
descrive above.  
C) Effects of SB105 and SB105_A10 on the replication of other viruses. NIH3T3 cells were 
infected with MCMV Smith, while HELF cells were infected with either adenovirus or VSV at an 
M.O.I. of 1 PFU/cell. The cells were pretreated and treated with increasing concentrations of SB105  
and SB105_A10 1 h prior to and during viral infection until an extensive viral cytopathic effect was 
observed in the untreated controls. The extent of virus replication was then assessed by titrating the  
infectivity of the supernatants of cell suspensions using a standard plaque assay. Plaques were 
microscopically counted and the mean plaque counts for each drug concentration are expressed as a 
percentage of the control mean count. Data shown represent the means ± SD (error bars) of three 
independent experiments. NIH3T3 cells viability was determined as descrive above. 
D) Inhibitory effect of SB105 and SB105_A10 on GCV-resistant HCMV TR and VR5438 
strains. HELF cells were infected with either HCMV VR5438 or HCMV TR (M.O.I. of 1  
PFU/cell) or underwent mock infection. Where indicated, cells were treated with increasing  
concentrations of dendrimers 1 h before, during virus adsorption and throughout the experiment  
until an extensive viral cytopathic effect was observed in the untreated control. The extent of  
VR5438 or TR replication was then assessed by titrating the infectivity of supernatants of cell  
suspensions on HELF cells using the IE antigen indirect immunoperoxidase staining technique. The  
results shown represent the means ± SD (error bars) of three independent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. SB105 prevents HCMV gene expression. (A) Effects of SB105 on HCMV IE, E and 
L proteins. HELF cells were either infected with HCMV AD169 at an M.O.I. of 1 PFU/cell or  
mock infected; where indicated, the cells were pretreated and treated with 2 M SB105 1 h prior to 
and throughout the infection period. Total cell extracts were prepared at increasing times p.i,  
fractionated by SDS-PAGE (50 g protein/lane) and analyzed by immunoblotting with anti-IEA 
(IE1 and IE2), anti-UL44 or anti-UL99 MAb. Actin immunodetection with a MAb served as an 
internal control. (B) IE gene expression is inhibited in cells treated with SB105. HELF cells were 
treated with SB105 and infected with HCMV AD169 as described in (A). Total RNA was isolated  
at the indicated time points after infection and subjected to reverse transcription. RT-PCR was then 
performed with the appropriate primers for IE1, IE2 and beta actin (as a control). For each 
timepoint, IE1 and IE2 RNA levels were normalized according to the expression of the actin gene. 
The data shown represent means ± SD (error bars) of three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. SB105 and SB105_A10 dendrimers prevent HCMV attachment. Prechilled HELF 
cells were treated with various concentrations of SB105, SB105 A_10, SB104 or heparin at 4 °C for 
1 h and then infected with 200 PFU of HCMV AD169 for 3 h at 4°C in the presence of the  
compounds as indicated. After virus adsorption, cells were then washed with cold medium three 
times to remove unattached virus and compounds, covered with 1.2% methylcellulose containing 
medium and incubated at 37°C. At six days p.i., viral plaques were stained and counted. The data  
shown represent means ± SD (error bars) of three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Preincubation of SB105 and SB105_A10 with virus does not affect HCMV 
infectivity. HCMV AD169 aliquots (104 PFU) were incubated for various lengths of time in the  
absence of dendrimers, or in the presence of 1 M SB105, SB105 A_10 or SB104 at either 4 or 
37°C. Following various incubation times, the samples were diluted to reduce peptide  
concentrations to a level below that at which HCMV replication is inhibited and the virus was then  
titrated on HELF cells. Plaques were microscopically counted and the mean plaque count for each 
peptide concentration expressed as PFU/ml on a log10 scale. The data shown represent means ± SD  
(error bars) of three independent experiments. 
 
 
 
 
Figure 7. SB105_A10 binds to cell surface heparan sulfate and inhibits HCMV adsorption. A)  
Effect of heparinase I or heparitinase I pretreatment of HELFs on binding of the labelled 
SB105_A10-FITC. HELFs monolayers were left untreated or treated with heparinase I (2.5  
units/ml) or heparitinase I (1 units/ml) for 1 h at 37°C, washed with medium and chilled at 4°C.  
Then, SB105_A10-FITC (1 M) was added alone, in the presence of a 10-fold molar excess of 
SB105_A10 or heparin (10 g/ml) for further 1 h at 4°C. Cells were then fixed, counterstained with 
Evans blue, and examined by fluorescence microscopy. The experiment was repeated twice, and  
representative images are presented. B) SB105_A10 inhibits the attachment of the reporter 
strain HCMV TB40 UL32-EGFP. HELFs were left untreated or digested with heparinase I (2.5 
units/ml) or heparitinase I (1 units/ml) for 1 h at 37°C, washed with medium, chilled at 4°C and  
infected with HCMV TB40 UL32-EGFP (M.O.I. of 20) in the presence of SB105_A10 (1 M) or 
heparin (10 g/ml) for 2 h at 4°C to allow for virus adsorption only. Cells were then fixed,  
counterstained with Evans blue, and examined by fluorescence microscopy to detect green  
fluorescent virus particles. The experiment was repeated twice, and representative images are 
presented. 
